What is Personalis?
Founded in 2011 and headquartered in Menlo Park, California, Personalis specializes in advanced genomic sequencing and analytic solutions. The company is a pivotal player in the development of personalized cancer vaccines and immunotherapies, providing the high-fidelity data necessary for precision medicine. By leveraging proprietary technology, Personalis enables researchers and clinicians to gain deeper insights into the molecular landscape of tumors, thereby facilitating the creation of highly tailored treatment protocols. Its market position is defined by its ability to bridge the gap between complex genomic data and actionable clinical insights, serving as a foundational partner for pharmaceutical and biotechnology companies engaged in oncology research.
How much funding has Personalis raised?
Personalis has raised a total of $233.5M across 5 funding rounds:
Series A
$20M
Series B
$22M
Series C
$33M
Stock Offering
$140.8M
Stock Offering
$17.7M
Series A (2011): $20M with participation from Abingworth, Stanford University, Lightspeed Venture Partners, and Mohr Davidow Ventures
Series B (2013): $22M led by Abingworth, Mohr Davidow Ventures, Wellington Shields & Co., and Lightspeed Venture Partners
Series C (2015): $33M supported by Mohr Davidow Ventures, Lightspeed Venture Partners, and Abingworth
Stock Issuance/Offering (2019): $140.8M, investors not publicly disclosed
Stock Issuance/Offering (2024): $17.7M backed by Tempus
Key Investors in Personalis
Abingworth
Abingworth is a leading transatlantic life sciences investment firm that helps transform cutting-edge science into novel medicines by providing capital and expertise to top-tier management teams.
Lightspeed Venture Partners
Lightspeed Venture Partners is a global multistage venture capital firm that invests in early and growth-stage technology companies across sectors such as enterprise software and infrastructure.
Tempus
Tempus AI, Inc. is a technology company operating at the intersection of artificial intelligence, machine learning, and advanced genomic diagnostics to transform clinical care.
What's next for Personalis?
Looking ahead, the strategic focus for Personalis centers on the integration of its genomic platforms with broader artificial intelligence and machine learning capabilities, as evidenced by its recent partnership and investment activity. The company is well-positioned to capitalize on the shift toward data-driven, precision-based therapeutic models. By continuing to expand its library of clinical and molecular data, Personalis aims to enhance its diagnostic accuracy and predictive modeling, which are essential for the next generation of targeted cancer therapies. Future growth will likely be driven by the commercialization of its diagnostic suite and the deepening of its collaborative efforts with major healthcare technology firms to streamline the path from genomic discovery to patient-specific clinical application.
See full Personalis company page
